chronic myelogenous leukemia, BCR-ABL1 positive (Cancer)
Information
- Disease name
- chronic myelogenous leukemia, BCR-ABL1 positive
- Disease ID
- DOID:0081088
- Description
- "A chronic myeloid leukemia that is characterized by an abnormally high number of neutrophils and the expression of the BCR-ABL1 fusion gene." [url:https\://pubmed.ncbi.nlm.nih.gov/32239758/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05972577 | Active, not recruiting | N/A | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | June 2, 2021 | December 31, 2024 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT00015834 | Completed | Phase 1/Phase 2 | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | May 2001 | |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00030394 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | September 2002 | |
| NCT00036738 | Completed | Phase 2 | Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | July 13, 2001 | May 2018 |
| NCT00049192 | Completed | Phase 2 | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | November 2002 | |
| NCT00054431 | Completed | Phase 2 | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | January 2003 | |
| NCT00003145 | Completed | Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia | August 1997 | |
| NCT00096161 | Completed | Phase 2 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | May 2003 | August 2015 |
| NCT00316953 | Completed | Phase 1 | Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | March 2006 | |
| NCT00351975 | Completed | Phase 1 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | June 2006 | March 2013 |
| NCT00702403 | Completed | Phase 1/Phase 2 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | August 14, 2008 | December 1, 2013 |
| NCT00796068 | Completed | Phase 2 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | February 24, 2009 | December 14, 2021 |
| NCT00060372 | Completed | Phase 1 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | April 2003 | |
| NCT00003694 | Completed | Phase 2 | Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | March 1999 | |
| NCT00006364 | Completed | Phase 2 | Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | November 1999 | |
| NCT01445080 | Completed | Phase 1/Phase 2 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | May 30, 2006 | December 10, 2012 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01789255 | Completed | Phase 2 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | June 2013 | March 2014 |
| NCT01858740 | Completed | Phase 2 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | April 10, 2014 | July 30, 2023 |
| NCT02210858 | Completed | Phase 1/Phase 2 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | May 2000 | March 2017 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT03128359 | Completed | Phase 2 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | May 30, 2017 | September 15, 2021 |
| NCT03267186 | Completed | Phase 2 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | September 12, 2017 | April 30, 2021 |
| NCT03941769 | Completed | Phase 1/Phase 2 | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | September 29, 2020 | March 1, 2023 |
| NCT04282343 | Completed | N/A | DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer | February 25, 2020 | October 21, 2022 |
| NCT04694820 | Completed | N/A | A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia | June 5, 2020 | April 8, 2022 |
| NCT03630991 | Recruiting | Phase 1 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | October 11, 2018 | April 30, 2025 |
| NCT03399773 | Recruiting | Phase 2 | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | May 10, 2022 | June 30, 2026 |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT01426334 | Terminated | Phase 1 | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | September 2011 | |
| NCT04083170 | Terminated | Phase 2 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | October 6, 2022 | November 30, 2022 |
| NCT01751425 | Terminated | Phase 1 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | July 24, 2013 | September 24, 2019 |
| NCT00101088 | Terminated | Phase 1 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | April 2005 | |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT00023920 | Terminated | Phase 2 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | July 2001 | |
| NCT03195010 | Terminated | Phase 2 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | June 9, 2017 | December 21, 2018 |
| NCT02730195 | Terminated | Phase 2 | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia | May 2016 | July 2018 |
| NCT03739606 | Withdrawn | Phase 2 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | October 20, 2020 | October 20, 2020 |
| NCT02734823 | Withdrawn | Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor | March 1, 2016 | March 14, 2024 | |
| NCT01670084 | Withdrawn | Phase 2 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia | December 2012 | September 2017 |
- Disase is a (Disease Ontology)
- DOID:8552
- Cross Reference ID (Disease Ontology)
- ICD9CM:205.1
- Cross Reference ID (Disease Ontology)
- ICDO:9875/3
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154592009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023473
- Exact Synonym (Disease Ontology)
- Chronic myelogenous leukemia, BCR/ABL positive